Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 128.31 <%= Resources.Global.txtUp %>
Updated 17:36:29
Change % 1.83% Stock price increasing
Change 2.30 Stock price increasing
Volume 333,073
High $ 128.73
Low $ 126.12
Open $ 126.48
ISIN
Prev close $ 126.01
# of shares 223.47M
Market cap 28,673M USD
Intraday

Alexion Pharmaceuticals Inc
Market is open (until 21:00) - Delayed 15 min
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  128.31 -6.7% Stock price decreasing -1.5% Stock price decreasing 12.3% Stock price increasing 3.5% Stock price increasing 19.0% Stock price increasing
Powered by TradingView

News about Alexion Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 April 2019 17:51:33
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB1 - 2019-04-22 18:51:33 - 2019-04-22 17:51:33 - 1000 - Website: OKAY